Market closed

Keros Therapeutics/$KROS

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Keros Therapeutics

Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.

Ticker

$KROS
Sector
Health Care
Trading on
NASDAQ

Industry

Biotechnology
Headquarters
Lexington, United States

Employees

160
Website
www.kerostx.com

KROS Metrics

BasicAdvanced
$519M
-
-$5.21
1.24
-

$519M

1.24

$73.00

$12.35

1.6M

19.031

18.361

3.271

3.62

-28.17%

-43.82%

686.921

0.94

0.94

-3.138

8,037.50%

5.09%

86.72%

24.72%

What the Analysts think about KROS

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Keros Therapeutics stock.

KROS Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

KROS Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-

KROS News

AllArticlesVideos
KROS ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Keros Therapeutics, Inc.

KROS ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Keros Therapeutics, Inc.

Accesswire·16 hours ago
An Investigation Has Commenced on Behalf of Keros Therapeutics, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your KROS Losses

An Investigation Has Commenced on Behalf of Keros Therapeutics, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your KROS Losses

Accesswire·2 days ago
KROS STOCK ALERT: Levi & Korsinsky Notifies Keros Therapeutics, Inc. Investors of an Ongoing Investigation

KROS STOCK ALERT: Levi & Korsinsky Notifies Keros Therapeutics, Inc. Investors of an Ongoing Investigation

Accesswire·4 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $KROS

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Keros Therapeutics stock?

Keros Therapeutics (KROS) has a market cap of $519M as of January 15, 2025.

What is the P/E ratio for Keros Therapeutics stock?

The price to earnings (P/E) ratio for Keros Therapeutics (KROS) stock is 0 as of January 15, 2025.

Does Keros Therapeutics stock pay dividends?

No, Keros Therapeutics (KROS) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Keros Therapeutics dividend payment date?

Keros Therapeutics (KROS) stock does not pay dividends to its shareholders.

What is the beta indicator for Keros Therapeutics?

Keros Therapeutics (KROS) has a beta rating of 1.24. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.